Evidence for base excision repair processing of DNA interstrand crosslinks

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 743-744, Issue , 2013, Pages 44-52

  Kothandapani, Anbarasi ^a   Patrick, Steve M ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

AP endonuclease; Base excision repair; BCNU; Cisplatin; DNA glycosylase; DNA Polymerase beta; Interstrand crosslinks; Mitomycin C; Nitrogen mustard; Oxaliplatin; Psoralen

Indexed keywords

3 ALKYLADENINE DNA GLYCOSYLASE; APHIDICOLIN; CARMUSTINE; CISPLATIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE 1; DNA DIRECTED DNA POLYMERASE BETA; DNA DIRECTED DNA POLYMERASE EPSILON; DNA DIRECTED DNA POLYMERASE GAMMA; DNA GLYCOSYLTRANSFERASE; DNA POLYMERASE; ENDONUCLEASE; MITOMYCIN; NEIL1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; PROTEIN FEN1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CHEMOSENSITIVITY; DNA CROSS LINKING; DNA HELIX; DNA REPLICATION; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME MECHANISM; EXCISION REPAIR; HUMAN; MISMATCH REPAIR; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SINGLE STRANDED DNA BREAK; STRUCTURE ACTIVITY RELATION;

ANIMALS; CROSS-LINKING REAGENTS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; HUMANS; RECOMBINATION, GENETIC;

MAMMALIA;

EID: 84877923913     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2012.11.007     Document Type: Review

References (157)

1. Altieri F., Grillo C., Maceroni M., Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid. Redox Signal. 2008, 10:891-937.
2. Reddy M.C., Vasquez K.M. Repair of genome destabilizing lesions. Radiat. Res. 2005, 164:345-356.
3. Peterson C.L., Cote J. Cellular machineries for chromosomal DNA repair. Genes Dev. 2004, 18:602-616.
4. Zharkov D.O. Base excision DNA repair. Cell. Mol. Life Sci. 2008, 65:1544-1565.
5. Wilson D.M., Thompson L.H. Life without DNA repair. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:12754-12757.
6. Baute J., Depicker A. Base excision repair and its role in maintaining genome stability. Crit. Rev. Biochem. Mol. Biol. 2008, 43:239-276.
7. David S.S., O'Shea V.L., Kundu S. Base-excision repair of oxidative DNA damage. Nature 2007, 447:941-950.
8. Maynard S., Schurman S.H., Harboe C., de Souza-Pinto N.C., Bohr V.A. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009, 30:2-10.
9. Hegde M.L., Hazra T.K., Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008, 18:27-47.
10. Frosina G., Fortini P., Rossi O., Carrozzino F., Raspaglio G., Cox L.S., Lane D.P., Abbondandolo A., Dogliotti E. Two pathways for base excision repair in mammalian cells. J. Biol. Chem. 1996, 271:9573-9578.
11. Podlutsky A.J., Dianova I.I., Podust V.N., Bohr V.A., Dianov G.L. Human DNA polymerase beta initiates DNA synthesis during long-patch repair of reduced AP sites in DNA. EMBO J. 2001, 20:1477-1482.
12. Fortini P., Dogliotti E. Base damage and single-strand break repair: mechanisms and functional significance of short- and long-patch repair subpathways. DNA Repair 2007, 6:398-409.
13. Dogliotti E., Fortini P., Pascucci B., Parlanti E. The mechanism of switching among multiple BER pathways. Prog. Nucleic Acid Res. Mol. Biol. 2001, 68(68):3-27.
14. Timofeyeva N.A., Koval V.V., Knorre D.G., Zharkov D.O., Saparbaev M.K., Ishchenko A.A., Fedorova O.S. Conformational dynamics of human AP endonuclease in base excision and nucleotide incision repair pathways. J. Biomol. Struct. Dyn. 2009, 26:637-652.
15. Bennett R.A.O., Wilson D.M., Wong D., Demple B. Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:7166-7169.
16. Sidorenko V.S., Nevinsky G.A., Zharkov D.O. Mechanism of interaction between human B-oxoguanine-DNA glycosylase and AP endonuclease. DNA Repair 2007, 6:317-328.
17. Kaina B., Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int. J. Clin. Pharmacol. Ther. 2002, 40:354-367.
18. Damia G., D'Incalci M. Mechanisms of resistance to alkylating agents. Cytotechnology 1998, 27:165-173.
19. Sobol R.W., Watson D.E., Nakamura J., Yakes F.M., Hou E., Horton J.K., Ladapo J., Van Houten B., Swenberg J.A., Tindall K.R., Samson L.D., Wilson S.H. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6860-6865.
20. Trivedi R.N., Almeida K.H., Fornsaglio J.L., Schamus S., Sobol R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005, 65:6394-6400.
21. Glazer P.M., Stachelek G.C., Dalal S., Sweasy J.B. Targeting base excision repair to potentiate cancer therapy. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:S21.
22. Sharma R.A., Dianov G.L. Targeting base excision repair to improve cancer therapies. Mol. Aspects Med. 2007, 28:345-374.
23. Wilson D.M., Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell. Mol. Life Sci. 2010, 67:3621-3631.
24. Reed A.M., Fishel M.L., Kelley M.R. Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol. 2009, 5:713-726.
25. Madhusudan S., Smart F., Shrimpton P., Parsons J.L., Gardiner L., Houlbrook S., Talbot D.C., Hammonds T., Freemont P.A., Sternberg M.J.E., Dianov G.L., Hickson I.D. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res. 2005, 33:4711-4724.
26. Hu H.Y., Horton J.K., Gryk M.R., Prasad R., Naron J.M., Sun D.A., Hecht S.M., Wilson S.H., Mullen G.P. Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping. J. Biol. Chem. 2004, 279:39736-39744.
27. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P.J., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H.M., de Bono J.S. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
28. Banerjee S., Kaye S.B., Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 2010, 7:508-519.
29. Kovtun I.V., McMurray C.T. Crosstalk of DNA glycosylases with pathways other than base excision repair. DNA Repair 2007, 6:517-529.
30. Martin S.A., McCabe N., Mullarkey M., Cummins R., Burgess D.J., Nakabeppu Y., Oka S., Kay E., Lord C.J., Ashworth A. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248.
31. Guainazzi A., Scharer O.D. Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy. Cell. Mol. Life Sci. 2010, 67:3683-3697.
32. Dronkert M.L.G., Kanaar R. Repair of DNA interstrand cross-links. Mutat. Res. DNA Repair 2001, 486:217-247.
33. Maganaschwencke N., Henriques J.A.P., Chanet R., Moustacchi E. The fate of 8-methoxypsoralen photoinduced crosslinks in nuclear and mitochondrial yeast DNA - comparison of wild-type and repair-deficient strains. Proc. Nat. Acad. Sci. U.S.A. Biol. Sci. 1982, 79:1722-1726.
34. Lawley P.D., Phillips D.H. DNA adducts from chemotherapeutic agents. Mut. Res. Fundam. Mol. Mech. Mutagen. 1996, 355:13-40.
35. Mcvey M. Strategies for DNA interstrand crosslink repair: insights from worms, flies, frogs, and slime molds. Environ. Mol. Mutagen. 2010, 51:646-658.
36. Shen X., Li L. Mutagenic repair of DNA interstrand crosslinks. Environ. Mol. Mutagen. 2010, 51:493-499.
37. Jonnalagadda V.S., Matsuguchi T., Engelward B.P. Interstrand crosslink-induced homologous recombination carries an increased risk of deletions and insertions. DNA Repair 2005, 4:594-605.
38. Scharer O.D. DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses. Chembiochem 2005, 6:27-32.
39. Vasquez K.M. Targeting and processing of site-specific DNA interstrand crosslinks. Environ. Mol. Mutagen. 2010, 51:527-539.
40. Panasci L., Xu Z.Y., Bello V., Aloyz R. The role of DNA repair in nitrogen mustard drug resistance. Anticancer Drugs 2002, 13:211-220.
41. Wynne P., Newton C., Ledermann J., Olaitan A., Mould T.A., Hartley J.A. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br. J. Cancer 2007, 97:927-933.
42. Spanswick V.J., Craddock C., Sekhar M., Mahendra P., Shankaranarayana P., Hughes R.G., Hochhauser D., Hartley J.A. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002, 100:224-229.
43. Nojima K., Hochegger H., Saberi A., Fukushima T., Kikuchi K., Yoshimura M., Orelli B.J., Bishop D.K., Hirano S., Ohzeki M., Ishiai M., Yamamoto K., Takata M., Arakawa H., Buerstedde J.M., Yamazoe M., Kawamoto T., Araki K., Takahashi J.A., Hashimoto N., Takeda S., Sonoda E. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 2005, 65:11704-11711.
44. Wood R.D. Mammalian nucleotide excision repair proteins and interstrand crosslink repair. Environ. Mol. Mutagen. 2010, 51:520-526.
45. Hinz J.M. Role of homologous recombination in DNA interstrand crosslink repair. Environ. Mol. Mutagen. 2010, 51:582-603.
46. Hlavin E.M., Smeaton M.B., Miller P.S. Initiation of DNA interstrand cross-link repair in mammalian cells. Environ. Mol. Mutagen. 2010, 51:604-624.
47. Knipscheer P., Raschle M., Smogorzewska A., Enoiu M., Ho T.V., Scharer O.D., Elledge S.J., Walter J.C. The fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009, 326:1698-1701.
48. Ho V., Scharer O.D. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ. Mol. Mutagen. 2010, 51:552-566.
49. Raschle M., Knipsheer P., Enoiu M., Angelov T., Sun J.C., Griffith J.D., Ellenberger T.E., Scharer O.D., Walter J.C. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 2008, 134:969-980.
50. Hlavin E.M., Smeaton M.B., Noronha A.M., Wilds C.J., Miller P.S. Cross-link structure affects replication-independent DNA interstrand cross-link repair in mammalian cells. Biochemistry 2010, 49:3977-3988.
51. Legerski R.J. Repair of DNA interstrand cross-links during S phase of the mammalian cell cycle. Environ. Mol. Mutagen. 2010, 51:540-551.
52. Mladenova V., Russev G. Enhanced repair of DNA interstrand crosslinks in S phase. FEBS Lett. 2006, 580:1631-1634.
53. Al-Minawi A.Z., Lee Y.F., Hakansson D., Johansson F., Lundin C., Saleh-Gohari N., Schultz N., Jenssen D., Bryant H.E., Meuth M., Hinz J.M., Helleday T. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res. 2009, 37:6400-6413.
54. Vasquez K.M., Legerski R.J. DNA interstrand crosslinks: repair, cell signaling, and therapeutic implications. Environ. Mol. Mutagen. 2010, 51:491-492.
55. Sarkar S., Davies A.A., Ulrich H.D., Mchugh P.J. DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase zeta. EMBO J. 2006, 25:1285-1294.
56. Muniandy P.A., Thapa D., Thazhathveetil A.K., Liu S.T., Seidman M.M. Repair of laser-localized DNA interstrand cross-links in G(1) phase mammalian cells. J. Biol. Chem. 2009, 284:27908-27917.
57. Clingen P.H., Arlett C.F., Hartley J.A., Parris C.N. Chemosensitivity of primary human fibroblasts with defective unhooking of DNA interstrand cross-links. Exp. Cell Res. 2007, 313:753-760.
58. Andreassen P.R., Ren K.Q. Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. Curr. Cancer Drug Targets 2009, 9:101-117.
59. Niedernhofer L.J., Odijk H., Budzowska M., van Drunen E., Maas A., Theil A.F., de Wit J., Jaspers N.G.J., Beverloo H.B., Hoeijmakers J.H.J., Kanaar R. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol. Cell. Biol. 2004, 24:5776-5787.
60. Hanada K., Budzowska M., Modesti M., Maas A., Wyman C., Essers J., Kanaar R. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J. 2006, 25:4921-4932.
61. Kuraoka I., Kobertz W.R., Ariza R.R., Biggerstaff M., Essigmann J.M., Wood R.D. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J. Biol. Chem. 2000, 275:26632-26636.
62. Sasaki M.S., Takata M., Sonoda E., Tachibana A., Takeda S. Recombination repair pathway in the maintenance of chromosomal integrity against DNA interstrand crosslinks. Cytogenet. Genome Res. 2004, 104:28-34.
63. Shen X., Jun S., O'Neal L.E., Sonoda E., Bemark M., Sale J.E., Li L. REV3 and REV1 play major roles in recombination-independent repair of DNA interstrand cross-links mediated by monoubiquitinated proliferating cell nuclear antigen (PCNA). J. Biol. Chem. 2006, 281:13869-13872.
64. Wang X., Peterson C.A., Zheng H.Y., Nairn R.S., Legerski R.J., Li L. Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol. Cell. Biol. 2001, 21:713-720.
65. Zheng H.Y., Wang X., Warren A.J., Legerski R.J., Nairn R.S., Hamilton J.W., Li L. Nucleotide excision repair- and polymerase eta-mediated error-prone removal of mitomycin C interstrand cross-links. Mol. Cell. Biol. 2003, 23:754-761.
66. Rink S.M., Solomon M.S., Taylor M.J., Rajur S.B., Mclaughlin L.W., Hopkins P.B. Covalent structure of A nitrogen mustard-induced DNA interstrand cross-link - An N7-to-N7 linkage of deoxyguanosine residues at the duplex sequence 5'-D(Gnc). J. Am. Chem. Soc. 1993, 115:2551-2557.
67. Kumaresan K.R., Ramaswamy M., Yeung A.T. Structure of the DNA interstrand cross-link of 4,5',8-trimethylpsoralen. Biochemistry 1992, 31:6774-6783.
68. Fagan P.A., Spielmann H.P., Sigurdsson S.T., Rink S.M., Hopkins P.B., Wemmer D.E. An NMR study of [d(CGCGAATTCGCG)](2) containing an interstrand cross-link derived from a distamycin-pyrrole conjugate. Nucleic Acids Res. 1996, 24:1566-1573.
69. Coste F., Malinge J.M., Serre L., Shepard W., Roth M., Leng M., Zelwer C. Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63angstrom resolution: hydration at the platinated site. Nucleic Acids Res. 1999, 27:1837-1846.
70. Huang H.F., Zhu L.M., Reid B.R., Drobny G.P., Hopkins P.B. Solution structure of A cisplatin-induced DNA interstrand cross-link. Science 1995, 270:1842-1845.
71. Lukin M., de los Santos C. NMR structures of damaged DNA. Chem. Rev. 2006, 106:607-686.
72. Kasparkova J., Vojtiskova M., Natile G., Brabec V. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem. Eur. J. 2008, 14:1330-1341.
73. Brabec V., Sip M., Leng M. DNA conformational change produced by the site-specific interstrand cross-link of trans-diamminedichloroplatinum(Ii). Biochemistry 1993, 32:11676-11681.
74. Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2001, 478:1-21.
75. Wilson D.M., Seidman M.M. A novel link to base excision repair?. Trends Biochem. Sci. 2010, 35:247-252.
76. Couve-Privat S., Mace G., Rosselli F., Saparbaev M.K. Psoralen-induced DNA adducts are substrates for the base excision repair pathway in human cells. Nucleic Acids Res. 2007, 35:5672-5682.
77. Kothandapani A., Dangeti V.S., Brown A.R., Banze L.A., Wang X.H., Sobol R.W., Patrick S.M. Novel role of base excision repair (BER) in mediating cisplatin cytotoxicity. J. Biol. Chem. 2011, 286:14564-14574.
78. McCullough A.K., Dodson M.L., Lloyd R.S. Initiation of base excision repair: glycosylase mechanisms and structures. Annu. Rev. Biochem. 1999, 68:255-285.
79. Engelward B.P., Dreslin A., Christensen J., Huszar D., Kurahara C., Samson L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J. 1996, 15:945-952.
80. Allan J.M., Engelward B.P., Dreslin A.J., Wyatt M.D., Tomasz M., Samson L.D. Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Cancer Res. 1998, 58:3965-3973.
81. Maor-Shoshani A., Meira L.B., Yang X.M., Samson L.D. 3-methyladenine DNA glycosylase ill important for cellular resistance to psoralen interstrand cross-links. DNA Repair 2008, 7:1399-1406.
82. Mattes W.B., Lee C.S., Laval J., OConnor T.R. Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis 1996, 17:643-648.
83. Roth R.B., Samson L.D. 3-methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res. 2002, 62:656-660.
84. Kisby G.E., Olivas A., Park T., Churchwell M., Doerge D., Samson L.D., Gerson S.L., Turker M.S. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair 2009, 8:400-412.
85. Paik J., Duncan T., Lindahl T., Sedgwick B. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. Cancer Res. 2005, 65:10472-10477.
86. Mace-Aime G., Couve S., Khassenov B., Rosselli F., Saparbaev M.K. The Fanconi anemia pathway promotes DNA glycosylase-dependent excision of interstrand DNA crosslinks. Environ. Mol. Mutagen. 2010, 51:508-519.
87. Liu B., Yang X.H., Wang K.M., Tan W.H., Li H.M., Tang H.X. Real-time monitoring of uracil removal by uracil-DNA glycosylase using fluorescent resonance energy transfer probes. Anal. Biochem. 2007, 366:237-243.
88. Guay D., Garand C., Reddy S., Schmutte C., Lebel M. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells. Cancer Sci. 2008, 99:762-769.
89. Zhang H.H., Mizumachi T., Carcel-Trullols J., Li L.W., Naito A., Spencer H.J., Spring P.M., Smoller B.R., Watson A.J., Margison G.P., Higuchi M., Fan C.Y. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis 2007, 28:1629-1637.
90. Grombacher T., Tomicic M., Digweed M., Kaina B. Overexpression of cDNA encoding FANCC, SPHAR, MPG, SNM1 or HA 3611 does not render CHO cells more resistant to DNA crosslinking agents. Anticancer Res. 1999, 19:1729-1735.
91. Rinne M.L., He Y., Pachkowski B.F., Nakamura J., Kelley M.R. N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts. Nucleic Acids Res. 2005, 33:2859-2867.
92. Abbotts R., Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 2010, 36:425-435.
93. Tell G., Quadrifoglio F., Tiribelli C., Kelley M.R. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox Signal. 2009, 11:601-619.
94. Bobola M.S., Blank A., Berger M.S., Stevens B.A., Silber J.R. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin. Cancer Res. 2001, 7:3510-3518.
95. Silber J.R., Bobola M.S., Blank A., Schoeler K.D., Haroldson P.D., Huynh M.B., Kolstoe D.D. The apurinic/apyrimidinic endonuclease activity of Apel/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res. 2002, 8:3008-3018.
96. Silber J.R., Bobola M.S., Blank A., Schoeler K.D., Haroldson P.D., Huynh M.B., Kolstoe D.D. The apurinic/apyrimidinic endonuclease activity of Apel/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res. 2003, 9:2877.
97. Kelley M.R., Cheng L., Foster R., Tritt R., Jiang J.Z., Broshears J., Koch M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin. Cancer Res. 2001, 7:824-830.
98. Kakolyris S., Kaklamanis L., Engels K., Turley H., Hickson I.D., Gatter K.C., Harris A.L. Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence. Cancer Res. 1997, 57:1794-1797.
99. Koukourakis M.I., Giatromanolaki A., Kakolyris S., Sivridis E., Georgoulias V., Funtzilas G., Hickson I.D., Gatter K.C., Harris A.L. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/REF-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50:27-36.
100. Robertson K.A., Bullock H.A., Xu Y., Tritt R., Zimmerman E., Ulbright T.M., Foster R.S., Einhorn L.H., Kelley M.R. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 2001, 61:2220-2225.
101. Wang D., Xiang D.B., Yang X.Q., Chen L.S., Li M.X., Zhong Z.Y., Zhang Y.S. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
102. Freitas S., Moore D.H., Michael H., Kelley M.R. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin. Cancer Res. 2003, 9:4689-4694.
103. Yang S., Irani K., Heffron S.E., Jurnak F., Meyskens F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005, 4:1923-1935.
104. Walker L.J., Craig R.B., Harris A.L., Hickson I.D. A role for the human DNA-repair enzyme Hap1 in cellular-protection against DNA-damaging agents and hypoxic stress. Nucleic Acids Res. 1994, 22:4884-4889.
105. McNeill D.R., Lam W., DeWeese T.L., Cheng Y.C., Wilson D.M. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol. Cancer Res. 2009, 7:897-906.
106. McNeill D.R., Wilson D.M. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol. Cancer Res. 2007, 5:61-70.
107. Liu L.L., Yan L., Donze J.R., Gerson S.L. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol. Cancer Ther. 2003, 2:1061-1066.
108. Moore D.H., Michael H., Tritt R., Parsons S.H., Kelley M.R. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin. Cancer Res. 2000, 6:602-609.
109. Xu Y., Moore D.H., Broshears J., Liu L.F., Wilson T.M., Kelley M.R. The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res. 1997, 17:3713-3719.
110. Wang D., Luo M.H., Kelley M.R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 2004, 3:679-686.
111. Ischenko A.A., Saparbaev M.K. Alternative nucleotide incision repair pathway for oxidative DNA damage. Nature 2002, 415:183-187.
112. Couve S., Mace-Aime G., Rosselli F., Saparbaev M.K. The human oxidative DNA glycosylase NEIL1 excises psoralen-induced interstrand DNA cross-links in a three-stranded DNA structure. J. Biol. Chem. 2009, 284:11963-11970.
113. Kikuchi K., Taniguchi Y., Hatanaka A., Sonoda E., Hochegger H., Adachi N., Matsuzaki Y., Koyama H., van Gent D.C., Jasin M., Takeda S. Fen-1 facilitates homologous recombination by removing divergent sequences at DNA break ends. Mol. Cell. Biol. 2005, 25:6948-6955.
114. Nikolova T., Christmann M., Kaina B. FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res. 2009, 29:2453-2459.
115. Zheng L., Dai H.F., Zhou M., Li M., Singh P., Qiu J.Z., Tsark W., Huang Q., Kernstine K., Zhang X.M., Lin D.X., Shen B.H. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat. Med. 2007, 13:812-819.
116. Mchugh P.J., Sones W.R., Hartley J.A. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol. Cell. Biol. 2000, 20:3425-3433.
117. Sato M., Girard L., Sekine I., Sunaga N., Ramirez R.D., Kamibayashi C., Minna J.D. Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. Oncogene 2003, 22:7243-7246.
118. Kim J.M., Sohn H.Y., Yoon S.Y., Oh J.H., Yang J.O., Kim J.H., Song K.S., Rho S.M., Yoo H.S., Kim Y.S., Kim J.G., Kim N.S. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin. Cancer Res. 2005, 11:473-482.
119. Iacobuzio-Donahue C.A., Maitra A., Olsen M., Lowe A.W., Van Heek N.T., Rosty C., Walter K., Sato N., Parker A., Ashfaq R., Jaffee E., Ryu B., Jones J., Eshleman J.R., Yeo C.J., Cameron J.L., Kern S.E., Hruban R.H., Brown P.O., Goggins M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 2003, 162:1151-1162.
120. Lam J.S., Seligson D.B., Yu H., Li A., Eeva M., Pantuck A.J., Zeng G., Horvath S., Belldegrun A.S. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int. 2006, 98:445-451.
121. Spiro C., McMurray C.T. Nuclease-deficient FEN-1 blocks rad51/BRCA1-mediated repair and causes trinucleotide repeat instability. Mol. Cell. Biol. 2003, 23:6063-6074.
122. Sharma S., Sommers J.A., Gary R.K., Friedrich-Heineken E., Hubscher U., Brosh R.M. The interaction site of flap endonuclease-1 with WRN helicase suggests a coordination of WRN and PCNA. Nucleic Acids Res. 2005, 33:6769-6781.
123. Sharma S., Otterlei M., Sommers J.A., Driscoll H.C., Dianov G.L., Kao H.I., Bambara R.A., Brosh R.M. WRN helicase and FEN-1 form a complex upon replication arrest and together process branch-migrating DNA structures associated with the replication fork. Mol. Biol. Cell 2004, 15:734-750.
124. Bornarth C.J., Ranalli T.A., Henricksen L.A., Wahl A.F., Bambara R.A. Effect of flap modifications on human FEN1 cleavage. Biochemistry 1999, 38:13347-13354.
125. Barnes C.J., Wahl A.F., Shen B.H., Park M.S., Bambara R.A. Mechanism of tracking and cleavage of adduct-damaged DNA substrates by the mammalian 5'- to 3'-exonuclease endonuclease RAD2 homologue 1 or flap endonuclease 1. J. Biol. Chem. 1996, 271:29624-29631.
126. Yamtich J., Sweasy J.B. DNA polymerase family X: function, structure, and cellular roles. Biochim. Biophys. Acta Proteins Proteomics 2010, 1804:1136-1150.
127. Sobol R.W., Horton J.K., Kuhn R., Gu H., Singhal R.K., Prasad R., Rajewsky K., Wilson S.H. Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature 1996, 379:183-186.
128. Allinson S.L., Dianova I.I., Dianov G.L. DNA polymerase beta is the major dRP lyase involved in repair of oxidative base lesions in DNA by mammalian cell extracts. EMBO J. 2001, 20:6919-6926.
129. Canitrot Y., Frechet M., Servant L., Cazaux C., Hoffmann J.B. Overexpression of DNA polymerase beta: a genomic instability enhancer process. FASEB J. 1999, 13:1107-1111.
130. Srivastava D.K., Husain I., Arteaga C.L., Wilson S.H. DNA polymerase beta expression differences in selected human tumors and cell lines. Carcinogenesis 1999, 20:1049-1054.
131. Albertella M.R., Lau A., O'Connor M.J. The overexpression of specialized DNA polymerases in cancer. DNA Repair 2005, 4:583-593.
132. Sweasy J.B., DiMaio D., Lang T., Dalai S., Maitra M., Starcevic D., Chikova A. Cancer-associated variants of DNA polymerase beta. Environ. Mol. Mutagen. 2007, 48:548.
133. Lang T.M., Dalal S., Chikova A., DiMaio D., Sweasy J.B. The E295K DNA polymerase beta gastric cancer-associated variant interferes with base excision repair and induces cellular transformation. Mol. Cell. Biol. 2007, 27:5587-5596.
134. Sweasy J.B., Dalal S., Lang T. A gastric cancer variant of DNA polymerase beta induces cellular transformation by a mutational mechanism. Environ. Mol. Mutagen. 2006, 47:415.
135. Sweasy J.B., Lang T., Starcevic D., Sunt K.W., Lai C.C., DiMaio D., Dalal S. Expression of DNA polymerase beta cancer-associated variants in mouse cells results in cellular transformation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14350-14355.
136. Raaphorst G.P., Cybulski S.E., Sobol R., Ng C.E. The response of human breast tumour cell lines with altered polymerase beta levels to cisplatin and radiation. Anticancer Res. 2001, 21:2079-2083.
137. Yang J., Parsons J., Nicolay N.H., Caporali S., Harrington C.F., Singh R., Finch D., D'Atri S., Farmer P.B., Johnston P.G., McKenna W.G., Dianov G., Sharma R.A. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010, 29:463-468.
138. Ochs K., Sobol R.W., Wilson S.H., Kaina B. Cells deficient in DNA polymerase beta are hypersensitive to alkylating agent-induced apoptosis and chromosomal breakage. Cancer Res. 1999, 59:1544-1551.
139. Moynihan K., Elion G.B., AliOsman F., Marcelli S., Keir S., Bigner D.D., Friedman H.S. Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. Cancer Chemother. Pharmacol. 1996, 38:349-354.
140. Raaphorst G.P., Ng C.E., Yang D.P. Comparison of response to radiation, hyperthermia and cisplatin in parental and polymerase beta knockout cells. Int. J. Hyperthermia 2002, 18:33-39.
141. Horton J.K., Baker A., Vande Berg B.J., Sobol R.W., Wilson S.H. Involvement of DNA polymerase beta in protection against the cytotoxicity of oxidative DNA damage. DNA Repair 2002, 1:317-333.
142. Horton J.K., Srivastava D.K., Zmudzka B.Z., Wilson S.H. Strategic down-regulation of DNA Polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents. Nucleic Acids Res. 1995, 23:3810-3815.
143. Boudsocq F., Benaim P., Canitrot Y., Knibiehler M., Ausseil F., Capp J.P., Bieth A., Long C., David B., Shevelev I., Frierich-Heinecken E., Hubscher U., Amalric F., Massiot G., Hoffmann J.S., Cazaux C. Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol. Pharmacol. 2005, 67:1485-1492.
144. Daube S.S., Tomer G., Livneh Z. Translesion replication by DNA polymerase delta depends on processivity accessory proteins and differs in specificity from DNA polymerase beta. Biochemistry 2000, 39:348-355.
145. Prakash S., Prakash L. Translesion DNA synthesis in eukaryotes: a one- or two-polymerase affair. Genes Dev. 2002, 16:1872-1883.
146. Sargent J.M., Elgie A.W., Williamson C.J., Taylor C.G. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Br. J. Cancer 1996, 74:1730-1733.
147. Odwyer P.J., Moyer J.D., Suffness M., Harrison S.D., Cysyk R., Hamilton T.C., Plowman J. Antitumor-activity and biochemical effects of aphidicolin glycinate (Nsc-303812) alone and in combination with cisplatin in-vivo. Cancer Res. 1994, 54:724-729.
148. Damia G., Tagliabue G., Zucchetti M., Davoli E., Sessa C., Cavalli F., Dincalci M. Activity of aphidicolin glycinate alone or in combination with cisplatin in A murine ovarian tumor resistant to cisplatin. Cancer Chemother. Pharmacol. 1992, 30:459-464.
149. Beketicoreskovic L., Osmak M. Modulation of resistance to cisplatin by amphotericin-B and aphidicolin in human larynx-carcinoma cells. Cancer Chemother. Pharmacol. 1995, 35:327-333.
150. Speit G., Schutz P., Hoffmann H. Enhancement of genotoxic effects in the comet assay with human blood samples by aphidicolin. Toxicol. Lett. 2004, 153:303-310.
151. Zhang N.X., Lu X.Y., Legerski R.J. Partial reconstitution of human interstrand cross-link repair in vitro: characterization of the roles of RPA and PCNA. Biochem. Biophys. Res. Commun. 2003, 309:71-78.
152. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., Lynch T.J., Neuberg D.S., Christiani D.C. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 2004, 22:2594-2601.
153. Shim H.J., Yun J.Y., Hwang J.E., Bae W.K., Cho S.H., Lee J.H., Kim H.N., Shin M.H., Kweon S.S., Lee J.H., Kim H.J., Chung I.J. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 2010, 101:1247-1254.
154. Weaver D.A., Crawford E.L., Warner K.A., Elkhairi F., Khuder S.A., Willey J.C. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer 2005, 4.
155. Zhang R., Niu Y.J., Zhou Y.K. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol. Lett. 2010, 192:108-114.
156. Thompson L.H., West M.G. XRCC1 keeps DNA from getting stranded. Mutat. Res. DNA Repair 2000, 459:1-18.
157. Zhu G.Y., Lippard S.J. Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize Cisplatin-DNA Interstrand Cross-Links. Biochemistry 2009, 48:4916-4925.